Package Insert: Information for the Patient
Lurasidone Hydrochloride 18.5 mg Film-Coated Tablets
Lurasidone Hydrochloride 37 mg Film-Coated Tablets
Lurasidone Hydrochloride 74 mg Film-Coated Tablets
Read this package insert carefully before you start taking this medicine because it contains important information for you.
Lurasidone cinfa contains the active substance lurasidone and belongs to a group of medicines called antipsychotics. It is used to treat the symptoms of schizophrenia in adults (18 years of age and older) and adolescents 13 to 17 years old. Lurasidone acts by blocking the brain receptors on which the substances dopamine and serotonin act. Dopamine and serotonin are neurotransmitters (substances that allow nerve cells to communicate with each other) that are involved in the symptoms of schizophrenia. By blocking these receptors, lurasidone helps to normalize brain activity, reducing the symptoms of schizophrenia.
Schizophrenia is a disorder with symptoms such as hearing, seeing or feeling things that do not exist, having false beliefs, excessive suspicion, withdrawal, incoherent speech and behavior, and absence of emotions. People who suffer from this disorder may feel depressed, anxious, guilty or tense. This medicine is used to improve their schizophrenia symptoms.
Do not take Lurasidone cinfa
Warnings and precautions
The full effect of this medicine may take several days or even weeks to appear. Consult your doctor if you have any doubts about this medicine.
Consult your doctor or pharmacist before taking lurasidone or during treatment, especially if:
If you meet any of these conditions, consult your doctor, as it may be necessary to adjust your dose, monitor you more closely, or discontinue treatment with lurasidone.
Children and adolescents
Do not administer to children under 13 years.
Other medicines and Lurasidone cinfa
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medicine. This is especially important if you are taking:
Inform your doctor if you are taking any of these medicines, as it may be necessary to change the dose of that medicine during treatment with lurasidone.
The following medicines may increase the concentration of lurasidone in your blood:
The following medicines may decrease the concentration of lurasidone in your blood:
Inform your doctor if you are taking any of these medicines, as it may be necessary to change your dose of lurasidone.
Taking Lurasidone cinfa with food, drinks and alcohol
Alcohol consumption should be avoided when taking this medicine, as it will have an additive negative effect.
Do not drink grapefruit juice while taking this medicine. Grapefruit may affect the action of this medicine.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, or intend to become pregnant, consult your doctor or pharmacist before using this medicine.
This medicine should not be taken during pregnancy unless agreed with your doctor.
If your doctor decides that the potential benefits of treatment during pregnancy outweigh the potential risks for the unborn child, your doctor will closely monitor your child after birth. This is because newborns of mothers who have used lurasidone in the last trimester (last three months) of pregnancy may experience the following symptoms:
• tremors, rigidity or muscle weakness, drowsiness, agitation, respiratory problems and difficulty feeding.
If your child develops any of these symptoms, consult your doctor.
The passage of lurasidone into breast milk is unknown. Inform your doctor if you are breastfeeding your child or intend to do so.
Driving and operating machinery
During treatment with this medicine, you may experience drowsiness, dizziness and vision problems (see section 4, Possible side effects). Do not drive, cycle or operate tools or machinery until you know that this medicine does not affect you negatively.
Lurasidone cinfa contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially "sodium-free".
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, ask your doctor or pharmacist again.
Your dose will be decided by your doctor and may depend on:
Adults (18 years or older)
The recommended initial dose is 37 mg once a day.
Your doctor may increase or decrease the dose within the range of 18.5 mg to 148 mg once a day. The maximum daily dose should not exceed 148 mg.
Adolescents 13 to 17 years
The recommended initial dose is 37 mg of lurasidone once a day.
The dose may be increased or decreased by your doctor within the dose range of 37 to 74 mg once a day. The maximum daily dose should not exceed 74 mg.
How to take Lurasidone cinfa
Swallow the tablet whole with water to mask its bitter taste. Take the dose regularly every day at the same time to make it easier to remember. Take this medication with food or immediately after eating, as this helps the body absorb the medication and allows it to work better.
If you take more Lurasidone cinfa than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
You may experience drowsiness, fatigue, abnormal body movements, difficulty staying upright and walking, low blood pressure-related dizziness, and abnormal heartbeats.
If you forget to take Lurasidone cinfa
Do not take a double dose to compensate for the missed doses. If you forget to take a dose, take the next dose on the following day after the missed dose. If you forget two or more doses, consult your doctor.
If you interrupt treatment with Lurasidone cinfa
If you stop taking this medication, you will lose its effects. Do not stop taking the medication unless your doctor tells you to, as symptoms may reappear.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Seek immediate medical attentionif you notice any of the following symptoms:
(hypersensitivity). These reactions are common (can affect 1 in 10 people)
Also, the following side effects may appear in adults:
Very common (can affect more than 1 in 10 people):
Common (can affect up to 1 in 10 people):
Uncommon (can affect up to 1 in 100 people):
Rare (can affect up to 1 in 1000 people):
Unknown frequency (cannot be estimated from available data):
In elderly people with dementia, there has been a small increase in the number of deaths in patients taking antipsychotic medications compared to those not taking them.
Adolescents may experience the following side effects:
Very common (can affect more than 1 in 10 people):
Common (can affect up to 1 in 10 people):
Uncommon (can affect up to 1 in 100 people):
Reporting of side effects
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and blister after “CAD”. The expiration date is the last day of the month indicated.
This medication does not require special conditions for conservation.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point of the pharmacy. Ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Lurasidone Hydrochloride Composition
Each 18.5 mg tablet contains hydrochloride of lurasidone equivalent to 18.6 mg of lurasidone.
Each 37 mg tablet contains hydrochloride of lurasidone equivalent to 37.2 mg of lurasidone.
Each 74 mg tablet contains hydrochloride of lurasidone equivalent to 74.5 mg of lurasidone.
Appearance of the product and contents of the package
Lurasidone Hydrochloride 18.5 mg film-coated tablets
Round, white or off-white, film-coated tablets, engraved with "LL" on one side and plain on the other, with a diameter of 6.1 mm.
Lurasidone Hydrochloride 37 mg film-coated tablets
Round, white or off-white, film-coated tablets, engraved with "LI" on one side and plain on the other, with a diameter of 8.1 mm.
Lurasidone Hydrochloride 74 mg film-coated tablets
Oval, pale green to green, film-coated tablets, engraved with "LH" on one side and plain on the other, with dimensions 12.1 mm x 7.1 mm.
Available in package sizes containing 28 tablets in unit dose blisters of OPA/Al/PVC//Al.
Marketing Authorization Holder
Cinfa, S.A.
Carretera Olaz-Chipi, 10. Industrial Estate Areta
31620 Huarte (Navarra) – Spain
Responsible for manufacturing
ELPEN Pharmaceutical Co Inc
Marathonos Ave. 95, Pikermi Attiki,
19009, Greece
or
Cinfa, S.A.
Carretera Olaz-Chipi, 10. Industrial Estate Areta
31620 Huarte (Navarra) – Spain
Last review date of this leaflet: September 2024
The detailed information of this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/)
You can access detailed and updated information about this medicine by scanning with your smartphone the QR code included in the leaflet and packaging. You can also access this information on the following internet address:https://cima.aemps.es/cima/dochtml/p/89812/P_89812.html
QR code to:https://cima.aemps.es/cima/dochtml/p/89812/P_89812.html
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.